Search
for
Sort by
Research 31–60 of 1000+
- Clinical Manifestations of Hyperandrogenism and Ovulatory Dysfunction Are Not Associated with His1058 C/T SNP (rs1799817) Polymorphism of Insulin Receptor Gene Tyrosine Kinase Domain in Kashmiri Women with PCOS
- Synthesis, Characterisation, andIn VitroAnticancer Activity of Curcumin Analogues Bearing Pyrazole/Pyrimidine Ring Targeting EGFR Tyrosine Kinase
- Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors
- 1323 Human dermal fibroblasts and mast cell populations are altered in hidradenitis suppurativa, with epithelial-mesenchymal-transition signals ameliorated by spleen tyrosine kinase antagonism.
- Cerebral Ischemia Related to Isotretinoin; Venlafaxine-Induced Alopecia; Cognitive Dysfunction with Tolterodine; Retinal Artery Occlusion after Injection of Long-Acting Risperidone; Olanzapine-Induced Chylomicronemia Presenting as Pancreatitis; Metabolic Effects of the Atypical Antipsychotics – an Editorial; Another Drug-Induced Pancreatitis – This One Caused by a Tyrosine Kinase Inhibitor; Suicide Attempts Related to Antidepressant Medications
- 2,3,7,8‐Tetrachlorodibenzo‐<i>p</i>‐dioxin causes an increase in protein kinases growth hepatic associated with epidermal factor receptor in the plasma membrane
- Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis
- The PDGF/PDGFR pathway as a drug target
- Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
- Nilontinib induced keratosis pilaris atrophicans
- Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
- Rapid hair depigmentation in patient treated with pazopanib
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- An overview of management of drug-induced hair and nail disorders
- Hair graying and loss induced by imatinib mesylate
- Gefitinib-induced hair alterations: Figure 1
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Periocular Manifestations of Afatinib Therapy
- Nilotinib-induced generalized keratosis pilaris: Report of a rare case
- Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature
- The Dark Side of Gefitinib: Reflectance Confocal Microscopy Applied to Hair Hyperpigmentation
- Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female
- Treatment of discoid lupus erythematosus scarring alopecia with deucravacitinib: A case report
- Drug-induced hair pigmentation: Clinical perspectives and updates
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata